T1	Participants 74 92	allergic rhinitis:
T2	Participants 208 242	persistent allergic rhinitis (PER)
T3	Participants 415 522	multicenter, randomized, controlled clinical trial on PER will be conducted at three institutions in China.
T4	Participants 608 642	240 eligible participants with PER
